Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 618INDUSTRY 231NIH 58NETWORK 26OTHER_GOV 3UNKNOWN 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Colorectal Neoplasms 1

Interventions

Cisplatin 49Capecitabine 42Radiotherapy 33Oxaliplatin 33Gemcitabine 33apatinib 32Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 20Nivolumab 19pembrolizumab 18fludarabine 18Metformin 16Exercise 16Radiation 15camrelizumab 14S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Lenalidomide × Clear all
NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Completed
60 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04065789 2022-01-27

KyDaR

Tel-Aviv Sourasky Medical Center

Phase 2 Completed
41 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04326296 2020-05-15

The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal Cancer

Henan Cancer Hospital

Phase 1 Unknown
33 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡